Press releases
4 June 2020, Zwingenberg

BRAIN AG successfully placed new capital for the financing of further growth

  • Around 10% new shares placed
  • Approximately EUR 15 million additional growth capital

The Management Board of BRAIN AG (Biotechnology Research And Information Network AG) has, with the approval of the Supervisory Board, successfully completed the issue of about 1.8 million new shares (corresponding to approx. 10% of the share capital) as part of a cash capital increase from authorised capital excluding subscription rights.

The new registered shares with no par value were allocated to institutional investors by way of an accelerated bookbuilding process and placed at an issue price of EUR 8.30 per new share. BRAIN's main shareholder participated in the capital increase.

Adriaan Moelker, CEO BRAIN AG, declares: “We expect that the cash inflow from the capital increase will accelerate the further development of our product pipeline. In addition, part of the proceeds will be used to finance acquisitions and the expansion of our production network.”

“We are very pleased that our investors are supporting us in the equity financing and are thus helping to drive BRAIN´s long-term growth path”, added Manfred Bender, CFO BRAIN AG.

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of “Nature’s Toolbox” are successfully applied in the chemicals, cosmetics and food industries. BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners, and the company’s own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, BRAIN AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 2016 as the first company in the bioeconomy. Further information is available at www.brain-biotech.com.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page